{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:49:45Z","timestamp":1781920185011,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006378","name":"Universitas Indonesia","doi-asserted-by":"publisher","award":["NK-1295-3904\/UN2.RST\/HKP.05.00\/2020"],"award-info":[{"award-number":["NK-1295-3904\/UN2.RST\/HKP.05.00\/2020"]}],"id":[{"id":"10.13039\/501100006378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Some anti-malarial drugs often cause haemolytic anaemia in glucose-6-phosphate-dehydrogenase deficiency (G6PDd) patients. This study aims to analyse the association of G6PDd and anaemia in malaria patients receiving anti-malarial drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A literature search was performed in major database portals. All studies searched using keywords with Medical Subject Headings (MeSH) were included, without date or language restriction. Pooled mean difference of haemoglobin and risk ratio of anaemia were analysed using RevMan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen studies comprising 3474 malaria patients that included 398 (11.5%) with G6PDd were found. Mean difference of haemoglobin in G6PDd\/G6PD normal (G6PDn) patients was \u2212\u00a00.16\u00a0g\/dL (95% CI \u2212\u00a00.48, 0.15; I<jats:sup>2<\/jats:sup> 5%, p\u2009=\u20090.39), regardless of the type of malaria and dose of drugs. In particular with primaquine (PQ), mean difference of haemoglobin in G6PDd\/G6PDn patients with dose\u2009&lt;\u20090.5\u00a0mg\/kg\/day was \u2212\u00a00.04 (95% CI \u2212\u00a00.35, 0.27; I<jats:sup>2<\/jats:sup> 0%, p\u2009=\u20090.69). The risk ratio of developing anaemia in G6PDd patients was 1.02 (95% CI 0.75, 1.38; I<jats:sup>2<\/jats:sup> 0%, p\u2009=\u20090.79).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Single or daily standard doses of PQ (0.25\u00a0mg\/kg\/day) and weekly PQ (0.75\u00a0mg\/kg\/week) did not increase the risk of anaemia in G6PDd patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-023-04493-7","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T11:02:39Z","timestamp":1678014159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association of G6PD status and haemolytic anaemia in patients receiving anti-malarial agents: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Erni J.","family":"Nelwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharifah","family":"Shakinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Pasaribu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"4493_CR1","unstructured":"WHO. World malaria report 2021 [Internet]. Geneva, World Health Organization, 2021. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2021. Accessed 23 Jun 2022."},{"key":"4493_CR2","unstructured":"Buku Saku Tatalaksana Kasus Malaria [Internet]. Jakarta: Subdit Malaria Direktorat P2PTVZ Kementerian Kesehatan Republik Indonesia; 2018. http:\/\/www.pdpersi.co.id\/kanalpersi\/data\/elibrary\/bukusaku_malaria.pdf. Accessed 17 Jul 2019."},{"issue":"6 Suppl","key":"4493_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4269\/ajtmh.16-0093","volume":"95","author":"C Surjadjaja","year":"2016","unstructured":"Surjadjaja C, Surya A, Baird JK. Epidemiology of Plasmodium vivax in Indonesia. Am J Trop Med Hyg. 2016;95(6 Suppl):121\u201332.","journal-title":"Am J Trop Med Hyg"},{"key":"4493_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.","journal-title":"Malar J"},{"key":"4493_CR5","doi-asserted-by":"publisher","unstructured":"Baird JK, Satyagraha AW, Bancone G. Glucose-6-phosphate dehydrogenase deficiency and primaquine hemolytic toxicity. In: Hommel M, Kremsner P, Krishna S (eds). Encyclopedia of malaria. New York: Springer Nature Reference. 2014; pp. 1\u201316. https:\/\/doi.org\/10.1007\/978-1-4614-8757-9_102-1","DOI":"10.1007\/978-1-4614-8757-9_102-1"},{"key":"4493_CR6","unstructured":"WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale (Policy brief) [Internet]. Geneva, World Health Organization. http:\/\/www.who.int\/malaria\/publications\/atoz\/g6pd-testing-pq-radical-cure-vivax\/en\/. Accessed 7 Aug 2022."},{"key":"4493_CR7","first-page":"601","volume":"67","author":"WHO Working Group","year":"1989","unstructured":"WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601\u201311.","journal-title":"Bull World Health Organ"},{"key":"4493_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12936-017-1989-3","volume":"16","author":"OA Uthman","year":"2017","unstructured":"Uthman OA, Graves PM, Saunders R, Gelband H, Richardson M, Garner P. Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malar J. 2017;16:346.","journal-title":"Malar J"},{"key":"4493_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2017-000415","volume":"2","author":"KIC Ong","year":"2017","unstructured":"Ong KIC, Kosugi H, Thoeun S, Araki H, Thandar MM, Iwagami M, et al. Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond. BMJ Glob Health. 2017;2: e000415.","journal-title":"BMJ Glob Health"},{"key":"4493_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"4493_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"key":"4493_CR12","unstructured":"Ottawa Hospital Research Institute [Internet]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 6 Jan 2022."},{"key":"4493_CR13","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [Internet]. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.52ccy41iwbon. Accessed 6 Jan 2022."},{"key":"4493_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002861","volume":"3","author":"T Leslie","year":"2008","unstructured":"Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJM, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province. Pakistan PLoS ONE. 2008;3: e2861.","journal-title":"Pakistan PLoS ONE"},{"key":"4493_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, V\u00e9lez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229\u201341.","journal-title":"N Engl J Med"},{"key":"4493_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1590\/S0037-86822004000300004","volume":"37","author":"MCM Silva","year":"2004","unstructured":"Silva MCM, Santos EB, Costal EG, Filho MGS, Guerreiro JF. P\u00f3voa MM [Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg\/kg\/day]. Rev Soc Bras Med Trop. 2004;37:215\u20137 (in Portuguese).","journal-title":"Rev Soc Bras Med Trop"},{"key":"4493_CR17","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciz122","volume":"69","author":"JD Brito-Sousa","year":"2019","unstructured":"Brito-Sousa JD, Santos TC, Avalos S, Fontecha G, Melo GC, Val F, et al. Clinical spectrum of primaquine-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency: a 9-year hospitalization-based study from the Brazilian Amazon. Clin Infect Dis. 2019;69:1440\u20132.","journal-title":"Clin Infect Dis"},{"key":"4493_CR18","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.297.20.2201","volume":"297","author":"T Leslie","year":"2007","unstructured":"Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJM, et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA. 2007;297:2201\u20139.","journal-title":"JAMA"},{"key":"4493_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190272","volume":"13","author":"GJH Bastiaens","year":"2018","unstructured":"Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gon\u00e7alves BP, et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials. PLoS ONE. 2018;13: e0190272.","journal-title":"PLoS ONE"},{"key":"4493_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.4269\/ajtmh.2009.09-0351","volume":"81","author":"AB Tiono","year":"2009","unstructured":"Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, et al. Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapson: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2009;81:969\u201378.","journal-title":"Am J Trop Med Hyg"},{"key":"4493_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12879-019-3862-1","volume":"19","author":"L Dysoley","year":"2019","unstructured":"Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, Top S, et al. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019;19:250.","journal-title":"BMC Infect Dis"},{"key":"4493_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/cix355","volume":"65","author":"RC Tine","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clin Infect Dis. 2017;65:535\u201343.","journal-title":"Clin Infect Dis"},{"key":"4493_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"4493_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.","journal-title":"Malar J"},{"key":"4493_CR25","unstructured":"Poirot EAM. Evaluating the safety of malaria treatment in glucose-6-phosphate dehydrogenase-deficient individuals: evidence and tools to support malaria elimination. [Internet]. UCSF; 2016. https:\/\/escholarship.org\/uc\/item\/21n0v4rj. Accessed 15 Dec 2021."},{"key":"4493_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/00034983.1981.11687489","volume":"75","author":"KK Khoo","year":"1981","unstructured":"Khoo KK. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol. 1981;75:591\u20135.","journal-title":"Ann Trop Med Parasitol"},{"key":"4493_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12916-015-0441-1","volume":"13","author":"S Kheng","year":"2015","unstructured":"Kheng S, Muth S, Taylor WRJ, Tops N, Kosal K, Sothea K, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13:203.","journal-title":"BMC Med"},{"key":"4493_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12936-018-2564-2","volume":"17","author":"S Avalos","year":"2018","unstructured":"Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, et al. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients. Malar J. 2018;17:415.","journal-title":"Malar J"},{"key":"4493_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154015","volume":"11","author":"B Ley","year":"2016","unstructured":"Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study. PLoS ONE. 2016;11: e0154015.","journal-title":"PLoS ONE"},{"key":"4493_CR30","doi-asserted-by":"publisher","DOI":"10.1088\/1755-1315\/125\/1\/012098","volume":"125","author":"JK Baird","year":"2018","unstructured":"Baird JK. Therapeutic principles of primaquine against relapse of Plasmodium vivax malaria. IOP Conf Ser: Earth Environ Sci. 2018;125: 012098.","journal-title":"IOP Conf Ser: Earth Environ Sci"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04493-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04493-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04493-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T11:02:48Z","timestamp":1678014168000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04493-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4493"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04493-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}